Penumbra Q4 2022 revenue $221.2M, up 8.4% YoY; operating income $4.8M vs loss $40.1M

Penumbra Inc

2022-FY EPS reported -$0.05 revenue$847,133,000

Q4 revenue $221.2M (+8.4% YoY, +10.5% constant currency); full year $847.1M (+13.3%).
US revenue Q4 $157.1M (+8.8%); vascular product revenue $129.7M (+14.2%), neuro $91.5M (+1.2%).
Gross margin improved to 62.6% from 61.5% YoY.
Operating income $4.8M vs loss $40.1M in Q4 2021; non-GAAP operating income $7.2M vs $2.5M.
Full year revenue $847.1M, up 13.3% YoY; US revenue $591.7M (+12.1%).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Penumbra Inc reported the fourth quarter ended December 31, 2022 results: revenue $221.2 million.

Period: the fourth quarter ended December 31, 2022
Revenue: $221.2 million
Result: reported results

Exact text from the filing

Revenue of $221.2 million for the fourth quarter of 2022, an increase of 8.4% compared to revenue of $204.0 million for the fourth quarter of 2021, or an increase of 10.5% in constant currency (a non-GAAP measure) 1 .

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Penumbra Inc reported the full year ended December 31, 2022 results: revenue $847.1 million.

Period: the full year ended December 31, 2022
Revenue: $847.1 million
Result: reported results

Exact text from the filing

Revenue of $847.1 million for the full year 2022, an increase of 13.3% compared to revenue of $747.6 million for the full year 2021, or an increase of 15.5% in constant currency 1 .

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Penumbra Inc filing history →

Source: SEC EDGAR

accession 0001321732-23-000032

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.